Healthcare ECONOMIST
SEPTEMBER 15, 2021
reduced smoking rates) is having an impact, but another key key question is, what is medical technologies are driving these gains? Is it new surgical techniques, better diagnostics, improved medical devices, or new pharmaceuticals? Across all 8 diseases 56% of the relative value came from pharmaceuticals.
HIT Consultant
FEBRUARY 28, 2024
Hanneman brings over 20 years of experience in the MedTech and pharmaceutical industries. She joins Philips from Stryker, a global medical technology company, where she currently serves as Controller and Head of Financial Planning & Analysis. Hanneman’s Bio/Background Ms. Prior to Stryker, Ms.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
HIT Consultant
APRIL 8, 2024
About Model N Model N is a leader in revenue optimization and compliance solutions, empowering companies in the pharmaceutical, medical technology, and high-tech sectors. Upon completion, Model N will become a privately held company and its shares will be delisted from any public stock exchange.
HIT Consultant
MARCH 18, 2024
These microservices, with 25 newly launched offerings, are poised to expedite healthcare workflows in drug discovery, medical imaging, and genomics analysis. Within the NVIDIA AI Enterprise 5.0 software platform, NIM provides elevated capabilities in generative biology, chemistry, and molecular prediction.
Healthcare ECONOMIST
MAY 30, 2023
Some policymakers have called for weakening of intellectual property protections for vaccines and other pharmaceutical products, with the aim to reduce the price and improve access to existing medical technologies, particularly in Eastern Europe and developing countries. The abstract is below.
HIT Consultant
AUGUST 30, 2023
AI also has the potential to identify, and even design, up to 50 new therapeutic drugs in the next decade, representing a $ 50 billion opportunity for the global pharmaceutical industry, with a 20-40% reduction in pre-clinical costs. IvorIvor has been in a candidate search for more than 30 years.
Healthcare ECONOMIST
MAY 18, 2023
Actual testimony ) Dr. Darius Lakdawalla Professor of Pharmaceutical Economics and Public Policy, USC Leonard D. He proposed a balanced policy approach that includes generous prescription drug coverage, drug prices aligned with the value delivered to patients, and robust competition within the pharmaceutical supply chain.
Expert insights. Personalized for you.
72 
Let's personalize your content